Literature DB >> 21518876

Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Megan K L MacLeod1, Amy S McKee, Alexandria David, Jieru Wang, Robert Mason, John W Kappler, Philippa Marrack.   

Abstract

Vaccines can greatly reduce the spread of and deaths from many infectious diseases. However, many infections have no successful vaccines. Better understanding of the generation of protective CD8 memory T cells by vaccination is essential for the rational design of new vaccines that aim to prime cellular immune responses. Here we demonstrate that the combination of two adjuvants that are currently licensed for use in humans can be used to prime long-lived memory CD8 T cells that protect mice from viral challenge. The universally used adjuvant, aluminum salts, primed long-lived memory CD8 T cells; however, effective cytotoxic T-cell differentiation occurred only in the presence of an additional adjuvant, monophosphoryl lipid A (MPL). MPL-induced IL-6 was required for cytotoxic differentiation. The IL-6 acted by inducing granzyme B production and reducing expression of inhibitory molecule PD1 on the surface of the primed CD8 T cells. CD8 memory T cells generated by antigen delivered with both aluminum salts and MPL provided significant protection from influenza A challenge. These adjuvants could be used in human vaccines to prime protective memory CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518876      PMCID: PMC3093483          DOI: 10.1073/pnas.1104588108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening.

Authors:  Mingjun Wang; Kasper Lamberth; Mikkel Harndahl; Gustav Røder; Anette Stryhn; Mette V Larsen; Morten Nielsen; Claus Lundegaard; Sheila T Tang; Morten H Dziegiel; Jørgen Rosenkvist; Anders E Pedersen; Søren Buus; Mogens H Claesson; Ole Lund
Journal:  Vaccine       Date:  2006-12-29       Impact factor: 3.641

2.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

Authors:  F Crawford; H Kozono; J White; P Marrack; J Kappler
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

3.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

4.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

5.  Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.

Authors:  J H C M Kreijtz; G de Mutsert; C A van Baalen; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

Review 6.  CD8+ T cell efficacy in vaccination and disease.

Authors:  Victor Appay; Daniel C Douek; David A Price
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response.

Authors:  António Peixoto; César Evaristo; Ivana Munitic; Marta Monteiro; Alain Charbit; Benedita Rocha; Henrique Veiga-Fernandes
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

9.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962

10.  Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets.

Authors:  A T Heiny; Olivo Miotto; Kellathur N Srinivasan; Asif M Khan; G L Zhang; Vladimir Brusic; Tin Wee Tan; J Thomas August
Journal:  PLoS One       Date:  2007-11-21       Impact factor: 3.240

View more
  61 in total

1.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

2.  Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6.

Authors:  Siddheshvar Bhela; Christine Kempsell; Monali Manohar; Margarita Dominguez-Villar; Russell Griffin; Pooja Bhatt; Pia Kivisakk-Webb; Robert Fuhlbrigge; Thomas Kupper; Howard Weiner; Clare Baecher-Allan
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

3.  Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination.

Authors:  Eléna Gonçalves; Olivia Bonduelle; Angèle Soria; Pierre Loulergue; Alexandra Rousseau; Marine Cachanado; Henri Bonnabau; Rodolphe Thiebaut; Nicolas Tchitchek; Sylvie Behillil; Sylvie van der Werf; Annika Vogt; Tabassome Simon; Odile Launay; Behazine Combadière
Journal:  J Clin Invest       Date:  2019-03-07       Impact factor: 14.808

Review 4.  Old and new adjuvants.

Authors:  Amy S McKee; Philippa Marrack
Journal:  Curr Opin Immunol       Date:  2017-07-19       Impact factor: 7.486

5.  Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Authors:  Diane G Edmondson; Sabitha Prabhakaran; Steven J Norris; Amy J Ullmann; Joe Piesman; Marc Dolan; Christian Probst; Christiane Radzimski; Winfried Stöcker; Lars Komorowski
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  Pathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation.

Authors:  Joshua J Obar; Evan R Jellison; Brian S Sheridan; David A Blair; Quynh-Mai Pham; Julianne M Zickovich; Leo Lefrançois
Journal:  J Immunol       Date:  2011-10-10       Impact factor: 5.422

7.  Significant role for IRF3 in both T cell and APC effector functions during T cell responses.

Authors:  Zacharey Guinn; Anna T Lampe; Deborah M Brown; Thomas M Petro
Journal:  Cell Immunol       Date:  2016-09-04       Impact factor: 4.868

Review 8.  Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Authors:  Audry Fernández; Liliana Oliver; Rydell Alvarez; Luis E Fernández; Kelvin P Lee; Circe Mesa
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation.

Authors:  Weiguo Cui; Nikhil S Joshi; Ying Liu; Hailong Meng; Steven H Kleinstein; Susan M Kaech
Journal:  J Immunol       Date:  2014-03-21       Impact factor: 5.422

Review 10.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.